m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00138)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
MIR107
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
RNA demethylase ALKBH5 (ALKBH5) [ERASER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting microRNA 107 (MIR107)/LATS2-mediated YAP activity in non-small cell lung cancer. | |||
Responsed Disease | Non-small-cell lung carcinoma | ICD-11: 2C25.Y | ||
Cell Process | Cell proliferation | |||
Cell invasion | ||||
Cell migration | ||||
Cell EMT | ||||
In-vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 |
BEAS-2B | Normal | Homo sapiens | CVCL_0168 | |
Calu-6 | Lung adenocarcinoma | Homo sapiens | CVCL_0236 | |
NCI-H1299 | Lung large cell carcinoma | Homo sapiens | CVCL_0060 | |
NCI-H520 | Lung squamous cell carcinoma | Homo sapiens | CVCL_1566 | |
In-vivo Model | For the experiments, mice were injected with 5 × 106 lung cancer cells with stably expression of relevant plasmids and randomly divided into indicated groups (five mice per group). To assess the in vivo effects of cycloleucine, the xenografted tumors had reached approximately 5 mm in diameter from mice and then these xenografted mice were feed with Vehicle or cycloleucine (25 mg/kg twice weekly) and tumor volume were measured every 3 day. Tumor volume was estimated as 0.5 × a2 × b (where a and b represent a tumors short and long diameter, respectively). Mice were euthanized after 7 weeks and the tumors were measured a final time. | |||
Lung cancer [ICD-11: 2C25]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting microRNA 107 (MIR107)/LATS2-mediated YAP activity in non-small cell lung cancer. | |||
Responsed Disease | Non-small-cell lung carcinoma [ICD-11: 2C25.Y] | |||
Target Regulator | RNA demethylase ALKBH5 (ALKBH5) | ERASER | ||
Cell Process | Cell proliferation | |||
Cell invasion | ||||
Cell migration | ||||
Cell EMT | ||||
In-vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 |
BEAS-2B | Normal | Homo sapiens | CVCL_0168 | |
Calu-6 | Lung adenocarcinoma | Homo sapiens | CVCL_0236 | |
NCI-H1299 | Lung large cell carcinoma | Homo sapiens | CVCL_0060 | |
NCI-H520 | Lung squamous cell carcinoma | Homo sapiens | CVCL_1566 | |
In-vivo Model | For the experiments, mice were injected with 5 × 106 lung cancer cells with stably expression of relevant plasmids and randomly divided into indicated groups (five mice per group). To assess the in vivo effects of cycloleucine, the xenografted tumors had reached approximately 5 mm in diameter from mice and then these xenografted mice were feed with Vehicle or cycloleucine (25 mg/kg twice weekly) and tumor volume were measured every 3 day. Tumor volume was estimated as 0.5 × a2 × b (where a and b represent a tumors short and long diameter, respectively). Mice were euthanized after 7 weeks and the tumors were measured a final time. | |||